Historial de carrera de Ingrid Boyes
Antiguos cargos conocidos de Ingrid Boyes.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MYOKARDIA, INC. | Oficial de Recursos Humanos | - | 01/01/2020 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Oficial de Recursos Humanos | 01/01/2006 | 01/01/2009 |
Corporate Officer/Principal | 01/01/1999 | 01/01/2009 |
Formación de Ingrid Boyes.
University of San Francisco | Undergraduate Degree |
Notre Dame de Namur University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
Human Resources Officer | 2 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Ingrid Boyes
- Experiencia